Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | EPOR | P19235 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21008369 | 1.00 | CA12 (0.33) | CA12CA1CA2CA4CA9 | |
| SCHEMBL24781307 | 0.95 | NR3C1 (0.35) | CA12CA1CA2CA4CA9 | |
| SCHEMBL18909059 | 0.94 | CA12 (0.34) | CA12CA1CA2CA4CA9 | |
| SCHEMBL23789199 | 0.94 | CA12 (0.34) | CA12CA1CA2CA4CA9 | |
| SCHEMBL19705582 | 0.92 | CA12 (0.34) | CA12CA1CA2CA4CA9 | |
| SCHEMBL17815411 | 0.92 | CA12 (0.34) | CA12CA1CA2CA4CA9 | |
| SCHEMBL17722949 | 0.92 | CA12 (0.34) | CA12CA1CA2CA4CA9 | |
| SCHEMBL22910463 | 0.91 | NR3C1 (0.35) | CA12CA1CA2CA4CA9 | |
| SCHEMBL19503143 | 0.91 | CA12 (0.33) | CA12CA1CA2CA4CA9 | |
| SCHEMBL22314188 | 0.91 | CA12 (0.33) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10383948-B2 | Anti-cMet antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2019-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10383948-B2 | Anti-cMet antibody drug conjugates and methods for their use | MMAB, HNMT, SHMT1 | CA12 585/4885CA1 3116/4885CA2 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.